Pfizer to Seek Emergency Authorization for COVID-19 Vaccine
WEDNESDAY, Oct. 28, 2020 -- In November, Pfizer plans to ask the U.S. Food and Drug Administration for emergency authorization for its COVID-19 vaccine after safety milestones are achieved, CBS News reported Tuesday.
Pfizer said its final vaccine trial has enrolled almost all of the planned 44,000 participants worldwide. Nearly 36,000 had received the second shot of the vaccine as of Monday. The trial includes people as young as 12 years and those with chronic, stable HIV, hepatitis C, and hepatitis B, CBS News reported.
Pfizer expects to know soon if the vaccine is effective or not -- Pfizer CEO Albert Bourla had said they expect to know if the vaccine works by the end of October.
The company has contracts with the United States, the European Union, and about 10 countries to deliver hundreds of millions of doses of the vaccine next year, assuming it is approved, CBS News reported.
© 2020 HealthDay. All rights reserved.
Posted: October 2020
Further Support and Information on COVID-19
Read this next
Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of Nov. 23 to 25, 2020. This roundup...
WEDNESDAY, Nov. 25, 2020 -- The Pfizer COVID-19 vaccine could start being distributed in the United States "soon after" a U.S. Food and Drug Administration advisory committee...
WEDNESDAY, Nov. 25, 2020 -- During a Thanksgiving week marred by the coronavirus pandemic, Anthony Fauci, M.D., spoke with HD Live! about the need for uniformity in response to...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.